SG11202004680UA - Cellular compositions and methods of treatment i - Google Patents

Cellular compositions and methods of treatment i

Info

Publication number
SG11202004680UA
SG11202004680UA SG11202004680UA SG11202004680UA SG11202004680UA SG 11202004680U A SG11202004680U A SG 11202004680UA SG 11202004680U A SG11202004680U A SG 11202004680UA SG 11202004680U A SG11202004680U A SG 11202004680UA SG 11202004680U A SG11202004680U A SG 11202004680UA
Authority
SG
Singapore
Prior art keywords
treatment
methods
cellular compositions
cellular
compositions
Prior art date
Application number
SG11202004680UA
Other languages
English (en)
Inventor
Peter Brink
Ira Cohen
Richard Lin
Sergey Doronin
Irina Potapova
Virginijus Valiunas
Dan Devine
Anthony Sandrasagra
Nick Loizos
Silviu Itescu
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of SG11202004680UA publication Critical patent/SG11202004680UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01214—Glycoprotein 3-alpha-L-fucosyltransferase (2.4.1.214)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202004680UA 2017-11-22 2018-11-21 Cellular compositions and methods of treatment i SG11202004680UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589764P 2017-11-22 2017-11-22
PCT/IB2018/001439 WO2019102268A1 (fr) 2017-11-22 2018-11-21 Compositions cellulaires et méthodes de traitement

Publications (1)

Publication Number Publication Date
SG11202004680UA true SG11202004680UA (en) 2020-06-29

Family

ID=65003422

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004680UA SG11202004680UA (en) 2017-11-22 2018-11-21 Cellular compositions and methods of treatment i

Country Status (10)

Country Link
US (1) US20210163932A1 (fr)
EP (1) EP3714038A1 (fr)
JP (1) JP7463275B2 (fr)
KR (1) KR20200088445A (fr)
CN (1) CN112004923A (fr)
AU (1) AU2018372631A1 (fr)
BR (1) BR112020010079A2 (fr)
CA (1) CA3084575A1 (fr)
SG (1) SG11202004680UA (fr)
WO (1) WO2019102268A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087139A2 (fr) 2006-01-13 2007-08-02 Osiris Therapeutics, Inc. CELLULES SOUCHES MÉSENCHYMATEUSES EXPRIMANT LE RÉCEPTEUR DU TNF-α
WO2020053186A1 (fr) * 2018-09-11 2020-03-19 Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Inhibiteurs de micro-arn a utiliser dans le traitement des maladies métaboliques
CN115287350A (zh) * 2020-03-30 2022-11-04 中国医学科学院肿瘤医院 包括外泌体miR-106b-3p、miR-10a-3p等在肺癌诊断中的应用
CN112067805B (zh) * 2020-08-25 2023-08-22 南通大学 一种β-1,4-半乳糖基转移酶-IsiRNA在克服肝癌化疗耐药药物中的应用
CN113025714B (zh) * 2021-03-23 2022-05-24 华中科技大学同济医学院附属同济医院 用于甲状腺乳头状癌颈侧方淋巴结转移诊断的miRNA生物标志物及检测试剂盒
WO2023019128A1 (fr) * 2021-08-09 2023-02-16 The Trustees Of The University Of Pennyslvania Optimisation de l'état de différenciation de lymphocytes t avec des micro-arn
WO2023109911A1 (fr) * 2021-12-15 2023-06-22 National Institute Of Biological Sciences, Beijing Microglie ayant un car et son utilisation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
WO1995002698A1 (fr) 1993-07-12 1995-01-26 Life Technologies, Inc. Compositions et procedes servant a transfecter des cellules eucaryotes
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
GB9519776D0 (en) 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
JP4399533B2 (ja) 2002-06-14 2010-01-20 キシンテラ、アクチボラグ 幹細胞のマーカーおよびその使用
US7842673B2 (en) * 2003-12-17 2010-11-30 The Trustees Of Columbia University In The City Of New York Delivery of DNA or RNA via gap junctions from host cells to target cells and a cell-based delivery system for antisense or siRNA
US20100047216A1 (en) * 2006-07-21 2010-02-25 Glenn Gaudette Compositions of late passage mesenchymal stem cells (mscs)
WO2008073919A2 (fr) * 2006-12-08 2008-06-19 Asuragen, Inc. Gènes et voies génétiques régulés par le mir-20 en tant que cibles en vue d'une intervention thérapeutique
WO2008141177A1 (fr) * 2007-05-11 2008-11-20 The Trustees Of Columbia University In The City Ofnew York Procédés et compositions pour le traitement du sarcome
US7615374B2 (en) 2007-09-25 2009-11-10 Wisconsin Alumni Research Foundation Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions
CA2756670A1 (fr) * 2009-03-26 2010-09-30 The Regents Of The University Of California Cellules souches mesenchymateuses produisant de l'arn inhibiteur pouvant etre utilisees pour agir sur le cours d'une maladie
JP6147191B2 (ja) 2010-11-02 2017-06-14 ヘルムホルツ−ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー 細胞不死化のための方法及びベクター
US8748470B2 (en) * 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
JP2015510401A (ja) * 2012-02-22 2015-04-09 ブレインステム バイオテック リミテッド ヒト疾患のインビトロモデル化および細胞に基づく治療のための間葉系幹細胞ならびにそのバンク
MX366900B (es) 2013-03-13 2019-07-30 Wisconsin Alumni Res Found Métodos y materiales para diferenciación hematoendotelial de células germinales pluripotentes humanas bajo condiciones definidas.
EP3142707A4 (fr) * 2014-05-13 2018-02-21 Sangamo Therapeutics, Inc. Méthodes et compositions pharmaceutiques pour la prévention ou le traitement d'une maladie
JP2017536127A (ja) 2014-11-24 2017-12-07 サイトストームアールエックス エルエルシー 炎症性疾患を治療するためのカプセル化幹細胞
EP3432714A4 (fr) * 2016-03-23 2019-11-13 The Trustees of Columbia University in the City of New York Traitement du cancer basé sur l'administration d'oligonucléotides par l'intermédiaire de jonctions lacunaires provenant de cellules souches mésenchymateuses humaines (hmsc)

Also Published As

Publication number Publication date
CA3084575A1 (fr) 2019-05-31
JP7463275B2 (ja) 2024-04-08
EP3714038A1 (fr) 2020-09-30
BR112020010079A2 (pt) 2020-11-03
WO2019102268A1 (fr) 2019-05-31
JP2021507683A (ja) 2021-02-25
US20210163932A1 (en) 2021-06-03
KR20200088445A (ko) 2020-07-22
CN112004923A (zh) 2020-11-27
AU2018372631A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
GB2582482B (en) CASZ compositions and methods of use
IL272627A (en) Terpene-enriched cannabinoid compositions and method of treatment
IL258955A (en) Preparations and methods for the treatment of cancer
GB2582100B (en) CAS12C Compositions and methods of use
IL268814A (en) Preparations and methods for the treatment of cancer
SG11202004680UA (en) Cellular compositions and methods of treatment i
ZA201906169B (en) Synthekine compositions and methods of use
HK1247789A1 (zh) 用於治療水腫的組合物和方法
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Preparations and methods of use
IL275182A (en) Preparations and methods for the treatment of metabolic conditions
EP3713583A4 (fr) Méthodes et compositions pour le traitement de la peau
HK1252057A1 (zh) 新穎的使用方法和組合物
HK1250345A1 (zh) 包含15-氧代-epa或15-氧代-dgla的組合物及其製備和使用方法
ZA201804380B (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
IL264977A (en) Methods and preparations for the treatment of melanoma
HK1255695A1 (zh) 用於治療眼瞼下垂的組合物和方法
GB201511799D0 (en) Composition and methods of treatment
GB201621737D0 (en) Compositions and methods of treatment
IL273850A (en) Preparations and methods for the treatment of leprosy
IL272147A (en) Methods and preparations for the treatment of cancer
SG11201705490QA (en) Mercaptanized vinylnorbornene compositions and methods of making same
GB201605127D0 (en) Composition and methods of treatment
GB201810923D0 (en) Compositions and method of treatment
IL261794A (en) Preparations and methods for using them